The Chain Mispairing Problem That Defines the Field
Chain mispairing has been the central manufacturing challenge for bispecific antibodies since the field’s outset, and every major structural format innovation in this landscape is, at its core, a solution to this single problem. When two distinct heavy chains and two distinct light chains are co-expressed in a single host cell, the combinatorial pairing possibilities generate homodimer byproducts alongside the desired heterodimer — complicating downstream purification and reducing yield of the target bispecific molecule.
The earliest entry in this dataset — a hybrid hybridoma-derived anti-CD3/anti-EGFR bispecific from Menarini Ricerche Sud S.p.A. (1995, Italy) — used protein A chromatography followed by cation exchange to separate the desired heterodimer from parental homodimers. That approach, relying on cell fusion rather than genetic engineering of chain pairing, illustrates how the mispairing challenge predates the modern era of antibody engineering by decades.
Contemporary solutions have diverged into four principal technical clusters: Fc-region engineering (knob-into-hole, Fab-arm exchange, common light chain), compact non-IgG formats (scFv, VHH nanobody fusions, tetravalent symmetric architectures), upstream continuous bioprocessing, and formulation science. According to WIPO‘s broader tracking of biopharmaceutical patent activity, bispecific antibodies now represent one of the most actively patented modalities in the global biologics space — a trend fully reflected in the filing density and geographic breadth of this dataset.
A bispecific antibody (BsAb) is an engineered immunoglobulin capable of simultaneously binding two distinct antigens or epitopes. Applications span oncology, autoimmunity, hematology, and ophthalmology. Manufacturing BsAbs presents unique challenges relative to conventional monoclonal antibodies, including chain mispairing, heterodimer assembly, purification complexity, and formulation stability.
Chain mispairing — the unintended pairing of heavy and light chains during bispecific antibody co-expression — is the defining manufacturing challenge in the bispecific antibody field, and the largest proportion of structural format patents in the 2026 landscape (including knob-into-hole, common light chain, Fab-arm exchange, symmetric tetravalent, and HCAb hybrid approaches) are all fundamentally solutions to this single problem.
Three Eras of Innovation: From Hybrid Hybridoma to Continuous Bioprocessing
The bispecific antibody manufacturing patent landscape, as represented in this dataset spanning 1995 to 2026, divides into three clearly demarcated eras — each defined by a distinct set of enabling technologies and a different cast of leading innovators.
The foundational period (1995–2010) is marked by a single entry: the hybrid hybridoma approach from Menarini (1995, Italy), representing early proof-of-concept manufacturing with limited format diversity and no genetic engineering of chain pairing. The structural engineering and platform buildout period (2010–2020) produced the most consequential manufacturing method patents in the dataset. Genmab A/S’s Fab-arm exchange (FAE) platform — first filed 2010, with multiple continuations through 2017 — became a foundational production method. Regeneron Pharmaceuticals’ common light chain strategy (2015), Amgen’s BiTE format scaling, and Chugai Seiyaku’s factor VIII cofactor-mimicking bispecific (2016) all emerged in this window. Click-chemistry approaches for forming chemically-locked heterodimers (Sorrento Therapeutics, 2020) appeared at the boundary of this era.
The scale-up, continuous manufacturing, and Chinese market entry period (2020–2026) is characterized by process intensification from Amgen (perfusion-based continuous manufacturing, 2019–2025), novel compact formats from Chinese biotechs including RemeGen, Betta Pharmaceuticals, WuXi Biologics, Biotheus, Harbour Biomed, Innovent Biologics, and Inmagene, and formulation engineering to address storage and administration challenges. Amgen’s 2025 active US patent for a continuous manufacturing process for bispecific antibody products signals continued platform consolidation at the industrial scale.
Map the full bispecific antibody patent landscape with PatSnap Eureka’s AI-native search and analysis tools.
Explore BsAb Patent Data in PatSnap Eureka →Fc Engineering and Format Strategies for Correct Heterodimerization
The dominant patent cluster in this dataset involves engineering the Fc CH3 domain to drive preferential heavy-chain heterodimerization, eliminating homodimer byproducts and simplifying downstream purification. Three principal techniques are evident, each with distinct IP ownership and manufacturing implications.
Fab-Arm Exchange (FAE)
Genmab A/S’s Fab-arm exchange platform — first filed 2010 in Israel, with multiple continuations through 2017 — is an ex vivo method in which two separate IgG4-like half-antibodies are produced independently, then combined under mild reducing conditions to undergo controlled disulfide-bond isomerization at the hinge, yielding near-quantitative bispecific product. The approach requires no co-expression of mismatched chains, making it both manufacturable and scalable. Genmab holds the foundational IP position on this approach with at least two distinct patent families in this dataset.
Knob-into-Hole and Charge-Pair Mutations
Knob-into-hole (KiH) and charge-pair mutation strategies are used extensively by F. Hoffmann-La Roche, Bristol-Myers Squibb, and Chinese biotechs. Amino acid substitutions in CH3 — for example, K213E/K147E and E123R/Q124K in the BCMA×CD3 format — steer preferential heavy chain pairing and reduce mispairing side products, facilitating purification. EngMab SARL’s 2023 filing covering a bispecific antibody against BCMA and CD3 for use in treating multiple myeloma applies this approach, as does Beijing Hanmi Pharmaceutical’s 2020 anti-PD-L1/anti-CD47 bispecific with a natural antibody-like heterodimer structure.
Common Light Chain (CLC) Strategy
Regeneron Pharmaceuticals holds key patents on the common light chain strategy (2015 and 2017 filings in Israel and Singapore), in which a single universal light chain is engineered to pair productively with two different heavy chains. This simplifies co-expression in a single host cell and eliminates light chain mispairing — a long-standing bottleneck distinct from heavy-chain mispairing. The CLC approach is particularly well-suited to fully human bispecific antibody production from transgenic animal platforms.
“Formulation science for bispecifics is an underserved IP sub-field: fewer than 8 filings address formulation stability as a primary claim, versus 50+ covering structure or target biology — a potential white space for IP capture.”
Genmab A/S’s Fab-arm exchange (FAE) platform — first filed in 2010 and extended through multiple continuations to 2017 — enables near-quantitative bispecific antibody production by co-incubating two IgG4-like half-antibodies under mild reducing conditions to achieve controlled disulfide-bond isomerization, requiring no co-expression of mismatched chains and representing one of the foundational production method patents in the bispecific antibody manufacturing field.
The application domains for these Fc-engineered bispecifics span oncology T cell redirection (BCMA×CD3 for multiple myeloma, CD19×CD3, DLL3×CD3 for small cell lung cancer), checkpoint dual blockade (PD-1/LAG3, PD-1/TIM3), and autoimmune cytokine dual blockade (IL-17A/F + IL-23, TNFα + IL-23, CGRP + IL-23). As documented by the European Medicines Agency, several bispecific antibodies using these engineering approaches have now progressed to regulatory approval across oncology indications, validating the manufacturing platforms at commercial scale.
Compact and Non-IgG Formats: scFv, VHH, and Chemical Conjugation
A second major cluster in this dataset covers bispecific formats that depart from full-length IgG architecture to achieve simpler expression, smaller molecular weight, or tunable valency — each with distinct manufacturing implications relative to conventional IgG-based bispecifics.
BiTE and Tandem scFv Formats
Amgen’s BiTE (Bispecific T cell Engager) format — two single-chain variable fragments (scFv) connected by a peptide linker, lacking Fc — was the first commercially validated compact bispecific format. More recently, Amgen has extended the BiTE platform with Fc domains for half-life extension. Key dataset entries include a 2018 Singapore filing and a 2016 Hungary filing from Amgen Research (Munich) GmbH covering bispecific T cell engaging antibody constructs. The absence of an Fc region simplifies the chain-pairing problem but introduces distinct challenges around half-life, immunogenicity, and continuous infusion requirements.
VHH-Based (Nanobody) Bispecifics
Single-domain antibody fragments (VHH) derived from camelid antibodies, fused to conventional IgG backbones, offer high thermal stability, ease of expression, and efficient purification — properties that directly address manufacturing yield and process development timelines. RemeGen Co., Ltd.’s 2025 filing in Israel uses VHH nanobody domains fused to conventional IgG for PD-1/VEGF dual targeting, explicitly citing advantages in thermal stability, purification tractability, and animal model cross-reactivity. Boehringer Ingelheim International GmbH’s 2013 filing also covers VHH-based bispecific binding molecules for anti-angiogenesis therapy. The VHH format is disproportionately represented among Chinese biotech filings in the 2022–2025 cohort.
Tetravalent Symmetric Formats
Wuhan YZY Biopharma Co., Ltd. has filed two patents (2022 in Europe, 2023 in the US) covering tetravalent symmetric bispecific antibodies — novel IgG-like architectures combining F(ab)₂-(Fv)₂-Fc arrangements in homodimeric configurations using identical heavy and light chains. The symmetric structure addresses classical manufacturing complexity by eliminating the need for heterodimeric chain engineering, at the cost of constraining valency and binding geometry.
Peptidic and Chemical Conjugation Bispecifics
Two early-stage but strategically significant approaches appear at the frontier of the dataset. The Hong Kong Polytechnic University’s 2023 WO filing describes a peptidic bispecific platform using one-pot chemical synthesis to attach cyclic tumor-targeting peptides to the surface of conventional monoclonal antibodies via bio-orthogonal click chemistry — producing a hybrid peptide-antibody bispecific without recombinant chain co-expression challenges. Sorrento Therapeutics’ 2020 European patent covers chemically-locked bispecific antibodies using similar click-chemistry approaches for forming covalently stabilized heterodimers. Both approaches remain earlier-stage relative to the established Fc engineering platforms, as tracked by research institutions including Nature‘s antibody engineering literature.
A 2024 WO filing from Zhejiang Shimai Pharmaceutical introduces protease-cleavable linkers into recombinant bispecific designs, enabling tumor-microenvironment-selective activation. This adds a precision selectivity layer to manufacturing design that requires controlled linker chemistry and stability testing — representing an emerging fifth manufacturing sub-challenge beyond chain mispairing.
VHH nanobody-based bispecific antibodies — single-domain antibody fragments derived from camelid antibodies fused to conventional IgG backbones — offer high thermal stability, ease of expression, and efficient purification, and are disproportionately represented among Chinese biotech patent filings in the 2022–2025 period, with RemeGen Co., Ltd. filing a VHH-based PD-1/VEGF bispecific in Israel in 2025.
Continuous Perfusion Manufacturing: Amgen’s Concentrated IP Position
Continuous perfusion manufacturing for bispecific antibodies is a strategically critical cluster in this dataset — and one that is concentrated almost exclusively in Amgen, representing a significant IP barrier for any organization seeking to implement continuous bioprocessing for bispecific products.
The core Amgen innovation is a two-loop perfusion strategy: a first control loop regulates medium level in the bioreactor; a second loop regulates viable cell biomass via permittivity or Raman probes, maintaining bioreactor product concentration below a threshold to minimize product-related impurities. This threshold control is an acute concern for labile bispecific formats, which often exhibit reduced conformational stability compared to their parental monospecific antibodies, making product concentration management during upstream processing a critical quality attribute.
The dataset contains at least 4–5 Amgen patent families covering perfusion bioreactor control for bispecific products across Canada, Singapore, the US, and Australia jurisdictions. A parallel 2021 Australian filing covers automated biomass-based perfusion control in biologics manufacturing more broadly. Genentech’s 2023 Japanese filing covers a distinct approach: prokaryotic expression of two-chain proteins in E. coli, with controlled growth/production phase temperature and agitation for two-chain assembly — representing an alternative to mammalian cell culture for bispecific upstream production.
Organizations seeking to implement continuous manufacturing processes for bispecifics face a concentrated IP barrier and should consider licensing strategies or design-around approaches, as noted in process analytical technology guidance from the US FDA. Amgen’s 2025 US active patent and parallel Australian 2025 pending filing indicate continued consolidation of perfusion-based continuous manufacturing as the industrial standard for bispecific antibody upstream production.
Identify design-around opportunities in continuous bispecific manufacturing IP with PatSnap Eureka’s AI-powered landscape analysis.
Analyse Manufacturing IP in PatSnap Eureka →Geographic and Assignee Landscape: Western Incumbents and Chinese Challengers
The geographic and assignee distribution of this dataset reveals a bimodal competitive structure: a small number of Western incumbents with deep, platform-level IP positions established between 2010 and 2020, and a rapidly expanding cohort of Chinese biotechs filing internationally at scale from 2022 onward.
Dominant Western Assignees
Among the retrieved results, six assignees account for the majority of filings. Amgen Inc. / Amgen Research (Munich) GmbH leads with approximately 10 filings, concentrated on continuous manufacturing, BiTE formats, and formulation. F. Hoffmann-La Roche AG / Hoffmann-La Roche Inc. accounts for approximately 8 filings covering PD1/TIM3, PD1/LAG3, and CEA/CD3 formulation. Ono Pharmaceutical Co., Ltd. (Japan) contributes approximately 7 filings on PD-1/CD19 and PD-1/CD3 autoimmune bispecifics. Genmab A/S holds approximately 4 filings but anchors the foundational Fab-arm exchange production method platform. Eli Lilly and Company (~3 filings) and RemeGen Co., Ltd. (~3 filings) round out the top six.
The Chinese Biotech Surge (2022–2025)
In this dataset, more than 8 Chinese-origin assignees appear in recent filings (2020–2025): RemeGen Co., Ltd.; WuXi Biologics (Ireland/Shanghai); Biotheus Inc.; Betta Pharmaceuticals Co., Ltd.; Wuhan YZY Biopharma Co., Ltd.; Harbour Biomed (Shanghai) Co., Ltd.; Innovent Biologics (Suzhou) Co., Ltd.; Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.; Excyte Biopharma Ltd.; Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; and AmpSource BioPharma Shanghai Inc. This cohort represents a major new entrant cluster concentrated in the 2020–2025 period, filing across Israel (IL), Australia (AU), PCT international (WO), Europe (EP), and the US — signaling an acceleration from preclinical to international patent prosecution stage, with competitive pressure on Western incumbents in Asia-Pacific markets.
Jurisdiction Distribution and What It Signals
Among retrieved results, the most frequently cited jurisdictions are: Israel (IL) — approximately 25 entries, used as a PCT national phase proxy by many applicants; Singapore (SG) — approximately 10 entries; Australia (AU) — approximately 8 entries; PCT international (WO) — approximately 8 entries; Europe (EP) — approximately 6 entries; Canada (CA) — approximately 5 entries; the US — approximately 3 entries; Japan (JP) — approximately 2 entries. The heavy representation of IL, SG, and AU filings reflects international patent prosecution strategies of both Western and Chinese innovators seeking broad geographic protection, rather than disproportionate market concentration in those countries.
US jurisdiction is notably underrepresented in the dataset relative to the actual size of the US bispecific antibody patent portfolio, suggesting the dataset is weighted toward PCT/national phase filings outside the US. According to EPO patent analytics, the US remains the largest single national jurisdiction for biopharmaceutical patent filings globally — making the US underrepresentation in this dataset a sampling artifact rather than a signal of reduced US innovation activity.
In the bispecific antibody manufacturing patent dataset covering 2020–2025, more than 8 Chinese-origin assignees — including RemeGen Co., Ltd., WuXi Biologics, Biotheus Inc., Betta Pharmaceuticals, Wuhan YZY Biopharma, Harbour Biomed, Innovent Biologics, and Inmagene Biopharmaceuticals — filed patents internationally across IL, AU, WO, EP, and US jurisdictions, primarily covering VHH nanobody fusions, PD-1/VEGF dual blockade, TGF-β/PD-L1, TNF-α/IL-23, and novel structural formats, representing a major new entrant cluster in the global bispecific antibody IP landscape.
Strategic Implications
Four strategic implications emerge from this landscape for R&D leaders and IP professionals entering or competing in the bispecific antibody manufacturing space:
- Platform selection is an early-stage IP decision. IP positions on Fc engineering approaches (knob-into-hole, CLC, FAE) are well-established among leading Western players. R&D teams must select or license one of these platform approaches early, as white space for foundational platform patents is limited.
- Continuous manufacturing IP is tightly held by Amgen. Organizations seeking to implement continuous manufacturing processes for bispecifics face a concentrated IP barrier across at least 4–5 Amgen patent families in CA, SG, US, and AU jurisdictions and should consider licensing strategies or design-around approaches.
- Formulation science represents an IP white space. Fewer than 8 filings in the dataset address formulation stability as a primary claim, versus 50+ covering structure or target biology. This imbalance represents a potential white space for IP capture, particularly for novel stabilization approaches (pH control, co-solute systems, lyophilization conditions) that address the known physicochemical liabilities of bispecifics.
- Novel synthesis modalities are early-stage but strategically important. The peptidic bispecific platform (Hong Kong Polytechnic University, 2023), chemically-locked IgG bispecifics (Sorrento, 2020), Genentech’s E. coli two-chain expression system (2021–2023), and protease-cleavable formats (Zhejiang Shimai, 2024) represent potential platform alternatives for organizations seeking freedom to operate outside the established Fc engineering IP thicket.